Davita Inc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $61.17 (market cap $44.49B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 3.9× Davita Inc's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and JPMorgan Nasdaq Equity Premium Income ETF for 65 Days on average.
| DVA | JEPQ | |
|---|---|---|
Market Cap | $11.29B | $44.49B |
Volume | 582,204 | 5,681,789 |
Sector | Health | Income / Options Overlay |
52-Week High | $240.96 | $61.46 |
52-Week Low | $103.87 | $53.77 |
Typical Hold Time | 113 Days | 65 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
JEPQ trades at $61.27, showing minimal daily movement with a 0.03% gain. The ETF maintains a bullish technical outlook with strong moving average support, though oscillators signal some near-term caution. Recent dividend distributions of $0.57-$0.70 demonstrate the fund's income generation capability, with financial media highlighting its 11% estimated yield and positioning for AI infrastructure growth.
The covered-call strategy provides downside protection but limits upside potential during strong bull markets. Institutional interest remains positive with recent acquisitions, though investors should note the variable nature of distributions and the trade-off between high current income and long-term capital appreciation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →